Skip to main content

Long-acting insulins

05-05-2023 | Insulin icodec | News

ONWARDS 2: Weekly insulin icodec superior to degludec in type 2 diabetes

The results of ONWARDS 2 show significantly improved glycemic control with weekly insulin icodec versus daily insulin degludec, without significantly increased hypoglycemia, in people with type 2 diabetes.

Pregnancy with insulin pen

01-10-2023 | Pregnancy | News

EXPECT: Degludec noninferior to detemir in pregnancy for type 1 diabetes

Pregnant women with type 1 diabetes can achieve similar glucose control regardless of whether they use insulin degludec or detemir, show the results of the randomised EXPECT trial.

06-15-2022 | Insulin | News

Liver-targeted insulin reduces hypoglycemic events

Switching 1% of standard bolus insulin lispro to a liver-targeted formulation decreases hypoglycemic events without affecting glucose control, OPTI-1 study findings indicate.

06-06-2022 | ADA 2022 | Conference coverage | News

​​​​​​​Hypoglycemia risk from insulin overdose no worse with icodec than glargine

The risk for hypoglycemia from an accidental basal insulin overdose is no higher with weekly insulin icodec than with daily glargine U100 in people with type 2 diabetes, report researchers.

05-26-2022 | Insulin glargine | News

Real-world support for adding Gla-300 to GLP-1 receptor agonists in type 2 diabetes

The addition of insulin glargine 300 units/mL to glucagon-like peptide-1 receptor agonist therapy in people with type 2 diabetes results in improved glycemic control without increasing risk for hypoglycemia, suggest findings from the real-world DELIVER-G study.

11-09-2021 | Travel | News

Insulin degludec could simplify travel across times zones

Insulin degludec offers similar glycemic outcomes to insulin glargine U100, along with more straightforward dosing, for people with insulin-treated diabetes crossing time zones, a small study suggests.

Woman applying diabetes medicine injection into her belly

10-19-2021 | Tirzepatide | News

Tirzepatide preferable to glargine when OADs fail in SURPASS-4

Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.

10-04-2021 | EASD 2021 | Conference coverage | News

Real-world data show comparable benefits for second-generation insulins in type 2 diabetes

Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.